Fairvalue-Calculator Fairvalue-Calculator
EN DE

Dicot Pharma AB (DICOT) Fair Value & Analysis

Healthcare · SE · Market cap 520M SEK

Pricekr 0.2050
Fair Valuekr 0.1000
Upside-51.2%
Quality95/100
Evidence: Low Range kr 0.0700 – kr 0.1200

Fair value as of: Jun 24, 2026

Analysis

Dicot Pharma AB (DICOT) currently trades at kr 0.2050, while our model-based Fair Value estimate is kr 0.1000 — implying the stock looks roughly 51.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Dicot Pharma AB (DICOT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 0.1000 versus a price of kr 0.2050 — about −51% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DICOT?
Our 21-model fair value for Dicot Pharma AB is kr 0.1000 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 0.2050.
What is the quality score of DICOT?
Dicot Pharma AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.